<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6750">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145403</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2014.010</org_study_id>
    <secondary_id>HUM00084170</secondary_id>
    <nct_id>NCT02145403</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies</brief_title>
  <official_title>Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The in vestigators are conducting a phase 1/2 study of fludarabine-based allo-HCT with the
      addition of carfilzomib in patients with hematologic malignancy.  The investigators
      hypothesize that adding carfilzomib to standard fludarabine-based conditioning regimen for
      allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant
      relapse and treatment-related mortality by decreasing severe GVHD, leading to overall
      improvement in transplant outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of patients who are alive and have not developed any &quot;event&quot;</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients who are alive and have not developed relapse/progression of primary disease or clinical grade III-IV acute graft-versus-host disease (GVHD) or chronic GVHD requiring systemic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression/ Relapse-free survival time</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from day 0 to the date of the first Progression/ Relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time from day 0 to the day of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of regimen related toxicities</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The type and number of adverse events related to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute GVHD</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cumulative incidence of acute Graft Versus Host Disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cumulative incidence of chronic Graft Versus Host Disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of non-relapse mortality</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The cumulative incidence of non-relapse mortality</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Allogeneic Transplantation</condition>
  <condition>Carfilzomib</condition>
  <condition>Relapse</condition>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Carfilzomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard fludarabine-based conditioning regimen (fludarabine + busulfan or fludarabine + melphalan), followed by an allogeneic hematopoietic cell transplantation, with the addition of carfilzomib.  Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.
Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels.</description>
    <arm_group_label>Carfilzomib</arm_group_label>
    <other_name>Kyprolis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine will be administered at 40 mg/m2/day IV x 4 on day -5 to day -2 when combined with busulfan (FluBu), or at 30 mg/m2 IV x 4 on day -5 to day -2 when combined with melphalan (FluMel).</description>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan will be administered at 3.2 mg/kg/day IV x 2 on day -5 to day -4 (FluBu2), or at 3.2 mg/kg/day IV x 4 on day -5 to day -2 (FluBu4).</description>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan will be administered at 140 mg/m2 IV x 1 on day -1 (FluMel 140) or at 180 mg/m2 IV x 1 on day -1 (FluMel 180).</description>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be administered at 5 mg/m2 IV per day on day +1, +3, +6 and +11 as standard graft-versus-host disease prophylaxis.</description>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.</description>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lymphoid or Myeloid malignancy requiring allogeneic hematopoietic cell
             transplantation

          -  Pathology review by the study institution is required

          -  Prior high-dose chemotherapy and autologous HCT(s) is (are) allowed

          -  Disease status: Stable disease or better at the time of enrollment

          -  Age: &gt;18 and &lt;65 years old at the time of transplant

          -  Life expectancy ≥ 6 months after transplant

          -  A 8/8 or 7/8 HLA-matched donor is available

          -  Karnofsky Performance Status &gt;70% (A measure of quality of life that ranges from 0 to
             100 where 100 equals perfect health and 0 is death.)

          -  Adequate cardiac [LVEF (Left Ventricular Ejection Fraction) &gt;0.4], pulmonary [FEV1
             (Forced Expiratory Volume in 1 Second), FVC (Forced Vital Capacity), corrected DLCO
             (Diffusing Capacity) ≥ 50% predicted], hepatic [DB (Direct Bilirubin) &lt;1.5xULN, AST
             (Aspartate Aminotransferase) / ALT (Alanine transaminase) ≤3xULN] and renal function
             [GFR (Glomerular Filtration Rate) ≥ 60 mL/min/1.73 m2]

        Exclusion Criteria:

          -  Progressive disease

          -  Active central nervous system involvement by malignancy

          -  Non compliance to medications or medical instructions

          -  Lack of appropriate caregivers

          -  Life expectancy &lt;6 months

          -  Pregnant or lactating females

          -  Uncontrolled infection requiring active treatment (systemic antibiotics, anti-virals,
             or anti-fungals) within 14 days

          -  HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity

          -  Active hepatitis A, B or C infection

          -  Unstable angina or myocardial infarction within 6 months prior to randomization, NYHA
             Class III or IV heart failure, uncontrolled angina, history of severe coronary artery
             disease, uncontrolled or persistent atrial fibrillation/flutter, history of
             ventricular fibrillation, ventricular tachycardia/torsade de pointes, sick sinus
             syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction
             system abnormalities unless subject has a pacemaker

          -  History of pulmonary hypertension

          -  Uncontrolled hypertension or uncontrolled diabetes mellitus

          -  Non-hematologic malignancy within the past 3 years with the exception of a)
             adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid
             cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason
             Grade 6 or less with stable prostate-specific antigen (PSA) levels; or d) cancer
             considered cured by surgical resection or unlikely to impact survival during the
             duration of the study, such as localized transitional cell carcinoma of the bladder
             or benign tumors of the adrenal or pancreas

          -  Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
             carfilzomib)

          -  Contraindication to any of the required concomitant drugs or supportive treatments,
             including hypersensitivity to all available anti-microbial drugs or intolerance to IV
             hydration due to pre-existing pulmonary or cardiac impairment

          -  Subjects with pleural effusion requiring thoracentesis or ascites requiring
             paracentesis within 14 days prior to admission

          -  Uncontrolled psychiatric condition

          -  Any other clinically significant medical or psychiatric disease or condition that, in
             the Investigator's opinion, may interfere with protocol adherence or a subject's
             ability to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attaphol Pawarode, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michgan Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Attaphol Pawarode, M.D.</last_name>
    <phone>734-936-8785</phone>
    <email>pawarode@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Attaphol Pawarode, M.D.</last_name>
      <phone>734-936-8785</phone>
      <email>pawarode@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Attaphol Pawarode, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan Cancer Center</investigator_affiliation>
    <investigator_full_name>Attaphol Pawarode, M.D.</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Transplantation</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Relapse</keyword>
  <keyword>Graft-Versus-Host Disease</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine monophosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
